title: High-level pacidamycin resistance in Pseudomonas aeruginosa is mediated by an opp oligopeptide permease encoded by the opp-fabI operon.
abstract: Pacidamycins (or uridyl peptide antibiotics) possess selective in vivo activity against Pseudomonas aeruginosa. An important limitation for the therapeutic use of pacidamycins with P. aeruginosa is the high frequency (10(-6) to 10(-7)) at which resistant mutants emerge. To elucidate the mechanism(s) of this resistance, pacidamycin-resistant P. aeruginosa mutants were isolated. Two types of mutants were obtained. Type 1, or high-level resistance mutants with a pacidamycin MIC of 512 μg/ml, were more abundant, with a frequency of~2 × 10(-6), and did not show cross-resistance with other antibiotics. Type 2, low-level resistance mutants, were isolated with a frequency of ~10(-8) and had a pacidamycin MIC of 64 μg/ml (the MIC for the wild-type strain was 4 to 16 μg/ml). These mutants were cross-resistant to levofloxacin, tetracycline, and erythromycin and were shown to overexpress either the MexAB-OprM or MexCD-OprJ multidrug resistance efflux pumps. High-level resistant mutants were isolated by transposon mutagenesis and one insertion was localized to oppB, one of two periplasmic binding protein components of an oligopeptide transport system which is encoded by the opp-fabI operon. The Opp system is required for uptake of pacidamycin across the inner membrane, since various opp, but not fabI, mutants were resistant to high levels of pacidamycin. Both of the two putative Opp periplasmic binding proteins, OppA and OppB, were required for pacidamycin uptake. Although both impaired uptake into and efflux from the cell can cause pacidamycin resistance in P. aeruginosa, our data suggest that impaired uptake is the primary reason for the high-frequency and high-level pacidamycin resistance.
authors: Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
authors: Anita
authors: A
authors: Mistry
authors: Mark S
authors: MS
authors: Warren
authors: John K
authors: JK
authors: Cusick
authors: RoxAnn R
authors: RR
authors: Karkhoff-Schweizer
authors: Olga
authors: O
authors: Lomovskaya
authors: Herbert P
authors: HP
authors: Schweizer
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics* / Q000378:metabolism; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects / Q000235:genetics*; D015964:Gene Expression Regulation, Bacterial; D008074:Lipoproteins / Q000235:genetics / Q000378:metabolism; D026901:Membrane Transport Proteins / Q000235:genetics* / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D059645:Mutation Rate; D009876:Operon; D010455:Peptides / Q000494:pharmacology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D011741:Pyrimidine Nucleosides / Q000494:pharmacology*; D014529:Uridine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D002352:Carrier Proteins; D008074:Lipoproteins; D026901:Membrane Transport Proteins; D010455:Peptides; D011741:Pyrimidine Nucleosides; C046506:oligopeptide-binding protein, bacteria; C588300:pacidamycin 4; C037230:oligopeptide permease, Bacteria; D014529:Uridine
references: Biotechniques. 2000 Nov;29(5):948-50, 952
references: 11084852
references: Antimicrob Agents Chemother. 1999 Jun;43(6):1340-6
references: 10348749
references: J Bacteriol. 1980 Jun;142(3):836-42
references: 6769912
references: J Antibiot (Tokyo). 1989 Apr;42(4):506-11
references: 2498263
references: J Antibiot (Tokyo). 1989 Apr;42(4):512-20
references: 2498264
references: Mol Gen Genet. 1972;114(2):134-43
references: 4622961
references: J Mol Biol. 1983 Jun 5;166(4):557-80
references: 6345791
references: Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16828-33
references: 20826445
references: J Bacteriol. 1980 May;142(2):474-9
references: 6991475
references: Nature. 2000 Aug 31;406(6799):959-64
references: 10984043
references: J Infect Chemother. 2003 Mar;9(1):101-3
references: 12673418
references: J Bacteriol. 1993 Nov;175(22):7363-72
references: 8226684
references: Plasmid. 2000 Jan;43(1):59-72
references: 10610820
references: Cancer. 1958 Mar-Apr;11(2):283-91
references: 13511347
references: Antimicrob Agents Chemother. 2001 Jan;45(1):105-16
references: 11120952
references: J Bacteriol. 1978 Mar;133(3):1113-25
references: 417059
references: J Bacteriol. 1999 Sep;181(17):5489-97
references: 10464225
references: Biotechniques. 1994 Sep;17(3):452-4, 456
references: 7818896
references: Antimicrob Agents Chemother. 1996 Jul;40(7):1640-4
references: 8807054
references: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14339-44
references: 14617778
references: J Bacteriol. 1989 Jul;171(7):3909-16
references: 2544562
references: Bioeng Bugs. 2011 Jul-Aug;2(4):218-21
references: 21829097
references: Antimicrob Agents Chemother. 1995 Sep;39(9):1948-53
references: 8540696
references: Methods Enzymol. 1994;235:386-405
references: 8057911
references: Gene. 1998 May 28;212(1):77-86
references: 9661666
references: J Bacteriol. 2012 Dec;194(23):6387-9
references: 22984262
references: Nucleic Acids Res. 2011 Jan;39(Database issue):D596-600
references: 20929876
references: J Antibiot (Tokyo). 1989 Apr;42(4):521-6
references: 2498265
references: Curr Top Med Chem. 2001 May;1(1):59-71
references: 11895293
references: Infect Immun. 2000 Dec;68(12):7069-77
references: 11083832
references: J Bacteriol. 2007 May;189(9):3392-402
references: 17322309